Processa Pharmaceuticals, Inc. current report, 28 October 2014

Business Context and Reporting Period

This Form 8-K was filed by Heatwurx, Inc. on November 3, 2014, reporting events occurring on October 28, 2014. The filing addresses the departure of a named executive officer and the appointment of interim financial leadership.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a one-time severance payment of $30,000 (less required deductions) to the departing executive.

Material Changes

  • Executive Departure: Alexander Kramer resigned as Chief Financial Officer (CFO), principal financial officer, and principal accounting officer effective October 28, 2014.
  • Interim Appointment: David Dworsky, the Company's President and CEO, will assume the roles of principal financial and accounting officer until a permanent replacement is hired.
  • Compensation Change: Mr. Dworsky will not receive additional compensation for these expanded responsibilities.

Outlook, Risks, and Unusual Items

Mr. Kramer stated he has no material disagreement with the Company regarding operations, policies, or practices. He has agreed to assist with transition needs. The Company is currently vetting candidates to hire a new CFO. The filing includes a Separation and Severance Agreement as an exhibit.

Investor Verification Checklist

  • Confirm the timeline for the appointment of a permanent CFO.
  • Review the full Separation and Severance Agreement (Exhibit 99.1) for any additional terms or conditions.
  • Monitor future filings for any financial reporting delays resulting from the interim leadership transition.